Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Acknowledgements
- Our research
- Using structure to find ligands
- Docking is one of the most efficient SBDD methods
- GPCRs transmit signals into cells
- Ligands have different effects on GPCRs
- GPCR conformation correlates with ligand efficacy
- Ligand conformation preference & efficacy
- The β2AR – X-ray structure at 2.40 Å
- Five known ligands of the β2AR
- Six potent (and novel) hits
- The hits are all inverse agonists
- Using two conformations leads to more agonists
- Identifying fragment-like binders
- Identifying selective compounds: CXCR3 & CXCR4
- Can we identify compounds with tailored selectivity?
- Finding dual binders is not trivial!
- Preserving important structural hallmarks
- Docking the same library twice with high hit rates
- Right for the right reasons? Different binding modes
- Validating the results: small molecule aggregation
- The limits of ligand selectivity: the A1AR
- Modeling A1AR should be easy, right?
- Homology modeling A1AR: iterative refinement
- All the little details matter!
- Modeling selectivity in the 3rd round
- No model was specific for A1AR
- All in all, 20 new ligands
- The compound most selective for A1AR
- Exploring chemical space for novel ligands
- How to find the right compounds in chemical space?
- The mathematical approach: enumerate all graphs
- In silico & synthetic medicinal chemistry
- SCUBIDOO
- Application to GPCRs yields (improved) ligands
- Sterically & chemically compatible building blocks
- Growing via Merging (GVM)
- Docking is great for finding ligands for GPCRs!
Topics Covered
- Structure-based drug design
- GPCRs and their conformational spectrum
- Docking to find selective ligands and ligands with tailored efficacy
- Expanding chemical space to address different GPCR conformations
Links
Series:
Categories:
External Links
Talk Citation
Kolb, P. (2021, February 25). Drugging conformational states of GPCRs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/TOVC7996.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
Other Talks in the Series: G Protein-Coupled Receptors (GPCRs) Signaling in Health and Disease
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, my name is Peter Kolb.
I'm from Philipps-University in Marburg,
the Department of Pharmaceutical Chemistry.
Today, I'm going to speak about drugging conformational states of GPCRs.
I'm going to showcase a few things that we have done over the past years, that highlight
the importance of addressing
the appropriate conformation of a G protein-coupled receptor.
0:25
Before I go into the research,
let me show you some of the people who have been contributing to this research,
most importantly Florent Chevillard,
but I'm also going to show you research by Dennis Schmidt and things that
we have done in collaboration with Jillian Baker at
Nottingham University, and also Brian Kobilka at Stanford University,
and a little bit of research that we have done with
Nuska Tschammer at Friedrich-Alexander-University in Erlangen.
0:54
I'm showing you a word cloud that exemplifies the research that we're doing.
You can see that receptors and G protein-coupled receptors
(GPCRs) are our most investigated targets.
We are trying to find ligands and inhibitors for these receptors,
agonists, inverse agonists, and antagonists.
We are trying to get more into the chemical space to find novel compounds,
novel molecules, that might have
novel effects and modulatory effects on the receptors and proteins in general.
1:26
This is my cartoon representation of what structure-based ligand discovery is.
We have a protein
(this is the box) that has binding pockets,
which are the holes in this box that you can see.
We have little blocks of different shapes, and we try to find
the block with the corresponding shape for a particular binding pocket.
Why is this something that you don't do in kindergarten any more?
The answer is that both the box as well as
the blocks that we have, change their shape so they are flexible.
Plus, we have in the order of tens of millions of
blocks that we can try to fit into any given binding pocket,
so this becomes a fundamentally harder problem.